8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Feb 26, 2026·SEC
BioLife Solutions, Inc.(BLFS)Earnings, Financials & Key Ratios
BLFS•NASDAQ
Price updated Jun 19, 2026
AboutBioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.Show more
- Revenue$96M+17.0%
- EBITDA-$9M-711.9%
- Net Income-$12M+39.9%
- EPS (Diluted)-0.25+43.2%
- Gross Margin64.56%-1.1%
- EBITDA Margin-9.74%-623.2%
- Operating Margin-12.61%-45.5%
- Net Margin-12.61%+48.6%
- ROE-3.37%+42.8%
BLFS Key Insights
BioLife Solutions, Inc. (BLFS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 14.9%
✗Weaknesses
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BLFS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BLFS Price & Volume
BioLife Solutions, Inc. (BLFS) stock price & volume — 10-year historical chart
Loading chart...
BLFS Growth Metrics
BioLife Solutions, Inc. (BLFS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years31.03%
5 Years14.88%
3 Years8.07%
TTM40.92%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-0.82%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM8.46%
Return on Capital
10 Years-7.98%
5 Years-4.43%
3 Years-3.74%
Last Year-3.24%
BLFS Recent Earnings
BioLife Solutions, Inc. (BLFS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.04+300.0%
$0.01
Rev
$28M+7.2%
$26M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.04+300.0%
$0.02
Rev
$25M+2.9%
$24M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.04+1900.0%
$0.00
Rev
$28M+9.3%
$26M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.33-888.5%
$0.03
Rev
$25M-1.0%
$26M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.04vs $0.01+300.0% | $28Mvs $26M+7.2% |
| Q1 2026 | Feb 26, 2026 | $0.04vs $0.02+300.0% | $25Mvs $24M+2.9% |
| Q4 2025 | Nov 6, 2025 | $0.04vs $0.00+1900.0% | $28Mvs $26M+9.3% |
| Q3 2025 | Aug 7, 2025 | $0.33vs $0.03-888.5% | $25Mvs $26M-1.0% |
Based on last 12 quarters of dataView full earnings history →
BLFS Peer Comparison
BioLife Solutions, Inc. (BLFS) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BFLY | 2.33B | 8.90 | -28.71 | 18.96% | -73.63% | -36.79% | 0.10 | |
 AZTA | 1.07B | 23.31 | -19.11 | 3.55% | -29.86% | -10.69% | 0.06 | |
 CYRX | 753.47M | 15.01 | 10.72 | -24.47% | 42.17% | 16.16% | 0.46 | |
 RGEN | 7.45B | 132.02 | 153.51 | 16.36% | 6.73% | 2.46% | 0.33 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 NVST | 4.22B | 25.91 | 92.54 | 8.32% | 2.41% | 2.18% | 0.55 | |
 FELE | 4.6B | 104.20 | 32.06 | 5.44% | 6.91% | 11.44% | 0.21 | |
 BNGO | 3.83M | 1.17 | -0.24 | -7.37% | -109.95% | -71.38% | 0.16 |
Compare BLFS vs Peers
BioLife Solutions, Inc. (BLFS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BLFS Income Statement
BioLife Solutions, Inc. (BLFS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 11.02M | 19.74M | 27.37M | 48.09M | 119.16M | 76.24M | 75.86M | 82.25M | 96.21M | 99.77M |
Revenue Growth % | 33.97% | 79.11% | 38.64% | 75.69% | 147.79% | -36.02% | -0.5% | 8.44% | 16.97% | 40.92% |
Cost of Goods Sold | 4.28M | 6.22M | 8.86M | 20.65M | 90.31M | 29.33M | 96.52M | 28.58M | 34.1M | 36.03M |
COGS % of Revenue | 38.8% | 31.49% | 32.36% | 42.93% | 75.79% | 38.47% | 127.24% | 34.75% | 35.44% | - |
Gross Profit | 6.75M▲ 0% | 13.53M▲ 100.5% | 18.51M▲ 36.9% | 27.44M▲ 48.2% | 28.85M▲ 5.1% | 46.91M▲ 62.6% | 46.75M▼ 0.3% | 53.67M▲ 14.8% | 62.12M▲ 15.7% | 63.74M▲ 0% |
Gross Margin % | 61.2% | 68.51% | 67.64% | 57.07% | 24.21% | 61.53% | 61.63% | 65.25% | 64.56% | 63.89% |
Gross Profit Growth % | 41.16% | 100.49% | 36.88% | 48.23% | 5.12% | 62.63% | -0.34% | 14.8% | 15.74% | - |
Operating Expenses | 7.8M | 9.86M | 18.17M | 30.77M | 73.34M | 52.83M | 117.58M | 60.8M | 74.25M | 74.63M |
OpEx % of Revenue | 70.79% | 49.96% | 66.4% | 63.99% | 61.55% | 69.3% | 155% | 73.92% | 77.17% | - |
Selling, General & Admin | 6.61M | 8.56M | 14.05M | 21.02M | 48.09M | 44.93M | 55.97M | 50.15M | 55.37M | 56.01M |
SG&A % of Revenue | 59.96% | 43.38% | 51.34% | 43.71% | 40.36% | 58.93% | 73.79% | 60.97% | 57.55% | - |
Research & Development | 1.19M | 1.3M | 4.12M | 6.72M | 11.82M | 14.8M | 18.8M | 7.91M | 7.57M | 8.14M |
R&D % of Revenue | 10.82% | 6.57% | 15.05% | 13.97% | 9.92% | 19.41% | 24.78% | 9.62% | 7.86% | - |
Other Operating Expenses | 0 | 0 | 0 | 3.03M | 13.43M | -6.89M | 42.81M | 2.74M | 11.31M | 0 |
Operating Income | -1.06M▲ 0% | 3.66M▲ 446.8% | -781K▼ 121.3% | -3.33M▼ 326.6% | -35.16M▼ 955.2% | -5.92M▲ 83.2% | -23.44M▼ 295.7% | -7.13M▲ 69.6% | -12.13M▼ 70.2% | -10.88M▲ 0% |
Operating Margin % | -9.58% | 18.55% | -2.85% | -6.93% | -29.51% | -7.77% | -30.9% | -8.67% | -12.61% | -10.91% |
Operating Income Growth % | 78.23% | 446.78% | -121.33% | -326.63% | -955.22% | 83.15% | -295.75% | 69.59% | -70.15% | - |
EBITDA | -717K | 4M | 1.53M | 1.74M | -22.3M | 14.04M | -11.14M | 1.53M | -9.38M | -6.08M |
EBITDA Margin % | -6.51% | 20.26% | 5.58% | 3.61% | -18.71% | 18.41% | -14.69% | 1.86% | -9.74% | -6.1% |
EBITDA Growth % | 84.01% | 657.88% | -61.8% | 13.61% | -1384.27% | 162.95% | -179.41% | 113.75% | -711.95% | -324.13% |
D&A (Non-Cash Add-back) | 339K | 338K | 2.31M | 5.07M | 12.87M | 19.96M | 12.29M | 8.66M | 0 | 4.8M |
EBIT | -2.13M | -25M | 770K | -3.59M | -30.65M | -10.68M | -25.63M | -7.13M | -9.38M | -12.26M |
Net Interest Income | -454K | 276K | 501K | 40K | -485K | -687K | -1.81M | -719K | -2.71M | 1.06M |
Interest Income | 1K | 281K | 506K | 58K | 0 | 0 | 0 | 0 | 0 | 1.72M |
Interest Expense | 455K | 5K | 5K | 18K | 485K | 687K | 1.81M | 719K | 2.71M | 660K |
Other Income/Expense | -1.46M | -28.67M | -2.98M | 0 | 6.13M | 1.07M | 4.97M | -4.3M | 49K | 486K |
Pretax Income | -2.52M▲ 0% | 3.27M▲ 229.9% | 9.52M▲ 191.5% | -1.28M▼ 113.5% | -29.03M▼ 2165.9% | -4.85M▲ 83.3% | -18.47M▼ 281.0% | -11.43M▲ 38.1% | -12.08M▼ 5.7% | -10.4M▲ 0% |
Pretax Margin % | -22.82% | 16.54% | 34.78% | -2.66% | -24.36% | -6.36% | -24.35% | -13.89% | -12.56% | -10.42% |
Income Tax | 0 | 396K | -1.54M | -3.26M | -20.12M | -5.24M | 24K | -38K | 49K | 97K |
Effective Tax Rate % | 0% | 12.12% | -16.19% | 254.8% | 69.31% | 108% | -0.13% | 0.33% | -0.41% | -0.93% |
Net Income | -2.52M▲ 0% | 3.27M▲ 229.9% | -1.66M▼ 150.7% | 2.67M▲ 261.0% | -8.91M▼ 434.0% | -139.81M▼ 1469.4% | -66.43M▲ 52.5% | -20.18M▲ 69.6% | -12.13M▲ 39.9% | -10.5M▲ 0% |
Net Margin % | -22.82% | 16.54% | -6.05% | 5.55% | -7.48% | -183.38% | -87.57% | -24.54% | -12.61% | -10.52% |
Net Income Growth % | 63.42% | 229.86% | -150.73% | 260.95% | -434.01% | -1469.43% | 52.49% | 69.61% | 39.9% | -0.82% |
Net Income (Continuing) | -2.52M | -25M | 0 | 1.98M | -8.91M | 388K | -18.45M | -11.39M | -12.13M | -10.5M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -140.19M | 0 | -8.8M | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.21▲ 0% | -1.56▼ 642.9% | -0.09▲ 94.5% | -0.06▲ 29.8% | -0.23▼ 284.6% | -3.29▼ 1330.4% | -1.52▲ 53.8% | -0.44▲ 71.1% | -0.25▲ 43.2% | -0.21▲ 0% |
EPS Growth % | 61.11% | -642.86% | 94.54% | 29.81% | -284.62% | -1330.43% | 53.8% | 71.05% | 43.18% | 8.46% |
EPS (Basic) | -0.21 | -1.56 | -0.09 | 0.07 | -0.23 | -3.29 | -1.52 | -0.44 | -0.25 | - |
Diluted Shares Outstanding | 13.26M | 16.26M | 19.46M | 27.31M | 38.5M | 42.48M | 43.72M | 46.07M | 48.65M | 49.25M |
Basic Shares Outstanding | 13.26M | 16.26M | 19.46M | 27.31M | 38.5M | 42.48M | 43.72M | 46.07M | 47.75M | 48.46M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
BLFS Balance Sheet
BioLife Solutions, Inc. (BLFS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 9.93M | 37.56M | 24.18M | 114.71M | 125.86M | 138.45M | 120.6M | 148.76M | 136.56M | 133.22M |
Cash & Short-Term Investments | 6.66M | 30.66M | 6.45M | 90.46M | 69.87M | 62.7M | 44.18M | 104.58M | 88.93M | 81M |
Cash Only | 6.66M | 30.66M | 6.45M | 90.46M | 69.87M | 19.44M | 27.9M | 95.39M | 33.04M | 22.82M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 43.26M | 16.29M | 9.2M | 55.89M | 58.17M |
Accounts Receivable | 1.02M | 3.04M | 5.34M | 8.01M | 23.22M | 33.94M | 18.66M | 9.17M | 7.95M | 13.06M |
Days Sales Outstanding | 33.81 | 56.3 | 71.28 | 60.77 | 71.12 | 162.47 | 89.77 | 40.68 | 30.17 | 38.33 |
Inventory | 1.85M | 3.51M | 11.12M | 11.6M | 28.34M | 34.9M | 43.46M | 29.01M | 30.16M | 32.83M |
Days Inventory Outstanding | 157.66 | 206.01 | 458.25 | 205.11 | 114.56 | 434.4 | 164.33 | 370.49 | 322.81 | 300.12 |
Other Current Assets | 0 | 0 | -85K | 0 | -229K | 6.91M | 14.31M | 6M | 9.53M | 6.33M |
Total Non-Current Assets | 2.21M | 7.9M | 68.83M | 120.12M | 426.75M | 311.78M | 292.11M | 250.73M | 269.32M | 267.68M |
Property, Plant & Equipment | 1.11M | 1.32M | 6.61M | 19.81M | 36.8M | 39.2M | 32.62M | 16.76M | 22.18M | 21.62M |
Fixed Asset Turnover | 9.97x | 14.97x | 4.14x | 2.43x | 3.24x | 1.94x | 2.33x | 4.91x | 4.34x | 6.93x |
Goodwill | 0 | 0 | 33.64M | 58.45M | 224.74M | 224.74M | 224.74M | 212.3M | 208.59M | 208.59M |
Intangible Assets | 0 | 0 | 21.98M | 31.05M | 152.15M | 32.09M | 21.15M | 9.56M | 4.26M | 3.93M |
Long-Term Investments | 1.07M | 6.55M | 2.5M | 5.87M | 4.37M | 6.4M | 13.33M | 5.62M | 31.25M | 55.03M |
Other Non-Current Assets | 35.84K | 36K | 3.92M | 4.71M | 9.81M | 9.35M | -20.88M | 6.48M | 3.05M | 33.55M |
Total Assets | 12.14M▲ 0% | 45.47M▲ 274.4% | 93.01M▲ 104.6% | 234.83M▲ 152.5% | 552.6M▲ 135.3% | 450.23M▼ 18.5% | 412.71M▼ 8.3% | 399.49M▼ 3.2% | 405.88M▲ 1.6% | 400.91M▲ 0% |
Asset Turnover | 0.91x | 0.43x | 0.29x | 0.20x | 0.22x | 0.17x | 0.18x | 0.21x | 0.24x | 0.25x |
Asset Growth % | 53.19% | 274.43% | 104.57% | 152.47% | 135.32% | -18.53% | -8.33% | -3.2% | 1.6% | 9.06% |
Total Current Liabilities | 1.51M | 1.94M | 7.78M | 15.57M | 42.7M | 44.58M | 42.18M | 32.73M | 22.98M | 18.25M |
Accounts Payable | 691K | 720K | 3.12M | 3.67M | 14.95M | 15.37M | 6.94M | 3.57M | 1.49M | 3.75M |
Days Payables Outstanding | 58.98 | 42.27 | 128.52 | 64.92 | 60.4 | 191.25 | 26.24 | 45.63 | 15.91 | 28.71 |
Short-Term Debt | 0 | 0 | 13K | 614K | 862K | 1.81M | 6.29M | 10.94M | 5M | 4.82M |
Deferred Revenue (Current) | 130K | 130K | 324K | 931K | 814K | 548K | 661K | 103K | 195K | 162K |
Other Current Liabilities | 130K | 159K | 1.96M | 6.34M | 21.52M | 20.71M | 23.21M | 5.23M | 5.93M | 9.69M |
Current Ratio | 6.56x | 19.37x | 3.11x | 7.37x | 2.95x | 3.11x | 2.86x | 4.54x | 5.94x | 7.30x |
Quick Ratio | 5.34x | 17.56x | 1.68x | 6.62x | 2.28x | 2.32x | 1.83x | 3.66x | 4.63x | 5.50x |
Cash Conversion Cycle | 132.49 | 220.04 | 401 | 200.96 | 125.28 | 405.62 | 227.86 | 365.55 | 337.07 | 309.75 |
Total Non-Current Liabilities | 538K | 380K | 2.21M | 14.01M | 33.54M | 41.46M | 32.87M | 17.84M | 11.02M | 10.42M |
Long-Term Debt | 0 | 0 | 0 | 655K | 6.35M | 23.79M | 17.56M | 5M | 0 | 10.04M |
Capital Lease Obligations | 0 | 0 | 550K | 8.77M | 16.76M | 15.09M | 8.7M | 12.72M | 10.66M | 22.25M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 5.49M | 250K | 114K | 124K | 189K | 751K |
Other Non-Current Liabilities | 538K | 28.9M | 0 | 4.51M | 4.94M | 2.33M | 6.5M | 0 | 171K | 183K |
Total Liabilities | 2.05M | 2.32M | 9.98M | 29.58M | 76.24M | 86.04M | 75.05M | 50.58M | 34M | 28.68M |
Total Debt | 0 | 0 | 1.35M | 11.15M | 26.88M | 43.71M | 33.83M | 30.17M | 17.9M | 14.86M |
Net Debt | -6.66M | -30.66M | -5.09M | -79.3M | -42.99M | 24.27M | 5.93M | -65.21M | -15.14M | -7.96M |
Debt / Equity | - | - | 0.02x | 0.05x | 0.06x | 0.12x | 0.10x | 0.09x | 0.05x | 0.04x |
Debt / EBITDA | - | - | 0.89x | 6.42x | - | 3.11x | - | 19.70x | - | -2.44x |
Net Debt / EBITDA | - | -7.66x | -3.33x | -45.68x | - | 1.73x | - | -42.57x | - | 1.31x |
Interest Coverage | -4.68x | -5000.00x | 154.00x | -199.28x | -63.19x | -15.54x | -14.15x | -9.92x | -3.46x | -18.58x |
Total Equity | 10.09M▲ 0% | 43.15M▲ 327.5% | 83.03M▲ 92.4% | 205.25M▲ 147.2% | 480.75M▲ 134.2% | 364.19M▼ 24.2% | 337.66M▼ 7.3% | 348.91M▲ 3.3% | 371.89M▲ 6.6% | 372.23M▲ 0% |
Equity Growth % | 218.76% | 327.55% | 92.42% | 147.21% | 134.23% | -24.25% | -7.28% | 3.33% | 6.59% | 28.83% |
Book Value per Share | 0.76 | 2.65 | 4.27 | 7.52 | 12.49 | 8.57 | 7.72 | 7.57 | 7.64 | 7.56 |
Total Shareholders' Equity | 10.09M | 43.15M | 83.03M | 205.25M | 480.75M | 364.19M | 337.66M | 348.91M | 371.89M | 372.23M |
Common Stock | 14.02K | 19K | 21K | 33K | 42K | 43K | 45K | 47K | 48K | 49K |
Retained Earnings | -73.96M | -71.03M | -100.05M | -97.39M | -105.02M | -246.91M | -313.34M | -335.1M | -339.7M | -338.51M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -2.01M | -2.33M | 0 | 0 | -282K | -679K | -345K | 24K | 132K | -120K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BLFS Cash Flow Statement
BioLife Solutions, Inc. (BLFS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 605K | 2.35M | 1.21M | 6.51M | -4.84M | -8.49M | -12.5M | 8.43M | 20.11M | 17.9M |
Operating CF Margin % | 5.49% | 11.89% | 4.43% | 13.55% | -4.06% | -11.13% | -16.48% | 10.25% | 20.91% | - |
Operating CF Growth % | 113.98% | 288.1% | -48.34% | 437.1% | -174.23% | -75.54% | -47.23% | 167.46% | 138.58% | 111.6% |
Net Income | -2.52M | 3.27M | -1.66M | 2.67M | -7.63M | -139.81M | -66.43M | -20.18M | 0 | -10.5M |
Depreciation & Amortization | 338.68K | 338K | 1.8M | 5.07M | 12.87M | 16.47M | 12.29M | 5.49M | 0 | 4M |
Stock-Based Compensation | 1.27M | 1.52M | 3.04M | 5.98M | 13.96M | 25.33M | 31.67M | 30.92M | 0 | 23.65M |
Deferred Taxes | 1M | 672K | -1.54M | -3.3M | -20.13M | -5.24M | -62K | -64K | 0 | 68K |
Other Non-Cash Items | 203.54K | -127K | 4.04M | -2.12M | -1.64M | 109.65M | 8.56M | -7.96M | 29.02M | 5.17M |
Working Capital Changes | 302.93K | -3.32M | -4.47M | -1.78M | -2.26M | -14.9M | 1.47M | 227K | -8.91M | -12.03M |
Change in Receivables | 172.33K | -2.02M | -290K | -1.79M | -10.13M | -10.75M | 15.35M | -2.9M | 264K | -4.84M |
Change in Inventory | -88.96K | -1.66M | -3.78M | -629K | 114K | -6.56M | -8.55M | 781K | -1.27M | -5.39M |
Change in Payables | 20.58K | -11K | 768K | -171K | 2.02M | 414K | -8.43M | 26K | -2.09M | 948K |
Cash from Investing | -144K | -6.5M | -27.02M | -23.73M | -12.64M | -58.12M | 17.84M | 58.3M | -71.54M | -46.19M |
Capital Expenditures | -143.77K | -500K | -675K | -4.63M | -8.38M | -10.38M | -6.38M | -3.23M | 0 | -9.47M |
CapEx % of Revenue | 1.3% | 2.53% | 2.47% | 9.63% | 7.04% | 13.62% | 8.41% | 3.92% | 9.85% | 9.49% |
Acquisitions | 0 | -6M | -22.19M | -15.94M | 1.56M | 0 | 0 | 60.39M | 0 | 33.74M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -233 | -6M | -1.66M | -3.17M | -5.82M | -3.54M | -4.86M | -2.37M | -71.54M | -20.65M |
Cash from Financing | 4.8M | 28.15M | 1.6M | 102.08M | -2.78M | 16.32M | 10.59M | -6.78M | -10.92M | -15.83M |
Debt Issued (Net) | 976K | 0 | 0 | 984K | -2.89M | 17.84M | -498K | -6.61M | -10M | -10M |
Equity Issued (Net) | 0 | 15.75M | 0 | 100.12M | 1.27M | 192K | 10.24M | 202K | 18K | 208K |
Dividends Paid | -106.25K | -436K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -4.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 3.93M | 12.83M | 1.6M | 973K | -1.16M | -1.71M | 845K | -377K | -942K | -6.04M |
Net Change in Cash | 5.26M▲ 0% | 23.99M▲ 356.4% | -24.21M▼ 200.9% | 84.01M▲ 447.0% | -20.59M▼ 124.5% | -50.4M▼ 144.8% | 15.96M▲ 131.7% | 59.95M▲ 275.5% | -62.35M▼ 204.0% | -44.12M▲ 0% |
Free Cash Flow | 461.23K▲ 0% | 1.85M▲ 300.7% | 538K▼ 70.9% | 1.88M▲ 249.8% | -13.22M▼ 802.5% | -18.87M▼ 42.8% | -18.88M▼ 0.0% | 5.2M▲ 127.6% | 10.64M▲ 104.4% | -1.79M▲ 0% |
FCF Margin % | 4.18% | 9.36% | 1.97% | 3.91% | -11.1% | -24.76% | -24.89% | 6.33% | 11.06% | -1.8% |
FCF Growth % | 108.26% | 300.67% | -70.89% | 249.81% | -802.5% | -42.76% | -0.03% | 127.56% | 104.4% | -115.89% |
FCF per Share | 0.03 | 0.11 | 0.03 | 0.07 | -0.34 | -0.44 | -0.43 | 0.11 | 0.22 | -0.04 |
FCF Conversion (FCF/Net Income) | -0.24x | 0.72x | -0.73x | 2.44x | 0.54x | 0.06x | 0.19x | -0.42x | -1.66x | 0.17x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BLFS Key Ratios
BioLife Solutions, Inc. (BLFS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -37.94% | 12.27% | -2.63% | 1.85% | -2.6% | -33.09% | -18.93% | -5.88% | -3.37% | -2.91% |
Return on Invested Capital (ROIC) | -19.72% | 34.5% | -1.3% | -2.45% | -9.36% | -1.08% | -4.8% | -1.7% | -2.84% | -2.32% |
Gross Margin | 61.2% | 68.51% | 67.64% | 57.07% | 24.21% | 61.53% | 61.63% | 65.25% | 64.56% | 63.89% |
Net Margin | -22.82% | 16.54% | -6.05% | 5.55% | -7.48% | -183.38% | -87.57% | -24.54% | -12.61% | -10.52% |
Debt / Equity | - | - | 0.02x | 0.05x | 0.06x | 0.12x | 0.10x | 0.09x | 0.05x | 0.04x |
Interest Coverage | -4.68x | -5000.00x | 154.00x | -199.28x | -63.19x | -15.54x | -14.15x | -9.92x | -3.46x | -18.58x |
FCF Conversion | -0.24x | 0.72x | -0.73x | 2.44x | 0.54x | 0.06x | 0.19x | -0.42x | -1.66x | 0.17x |
Revenue Growth | 33.97% | 79.11% | 38.64% | 75.69% | 147.79% | -36.02% | -0.5% | 8.44% | 16.97% | 40.92% |
Related:BLFS Dividend History·BLFS Revenue History·BLFS Price History·BLFS P/E History·BLFS Financial Ratios·BLFS Institutional Holders
BLFS SEC Filings & Documents
BioLife Solutions, Inc. (BLFS) SEC filings — annual & quarterly reports (10-K, 10-Q)
BLFS Frequently Asked Questions
BioLife Solutions, Inc. (BLFS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioLife Solutions, Inc. (BLFS) reported $99.8M in revenue for fiscal year 2025. This represents a 634% increase from $13.6M in 1995.
BioLife Solutions, Inc. (BLFS) grew revenue by 17.0% over the past year. This is strong growth.
BioLife Solutions, Inc. (BLFS) reported a net loss of $10.5M for fiscal year 2025.
Dividend & Returns
BioLife Solutions, Inc. (BLFS) has a return on equity (ROE) of -3.4%. Negative ROE indicates the company is unprofitable.
BioLife Solutions, Inc. (BLFS) had negative free cash flow of $1.8M in fiscal year 2025, likely due to heavy capital investments.